SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 19, 2011
Adeona Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
Nevada
(State or other jurisdiction of incorporation)
|
01-12584
|
13-3808303
|
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
3985 Research Park Drive, Suite 200
Ann Arbor, MI 48108
(Address of principal executive offices and zip code)
(734) 332-7800
(Registrant’s telephone number including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07 Submission of Matters to a Vote of Security Holders.
On July 19, 2011, Adeona Pharmaceuticals, Inc. (“Adeona”) held its Annual Meeting of Stockholders (the “Meeting”). The matters voted on at the Meeting were: (1) the election of five directors: (a) Steve H. Kanzer, (b) Jeffrey J. Kraws, (c) James S. Kuo, (d) Jeff Riley, and (e) Jeff Wolf and (2)ratification of the Board’s appointment of Berman & Company, P.A. as the Company’s independent registered public accounting firm for the year ending December 31, 2011. The terms of each of the following directors continued after the meeting: Steve H. Kanzer, Jeffrey J. Kraws, James S. Kuo, Jeff Riley, and Jeff Wolf. As of the record date for the meeting, there were 29,467,361 shares of common stock were issued and 28,038,789 shares of common stock were outstanding, each of which was entitled to one vote with respect to each of the matters voted on at the meeting. Each of the directors up for reelection was reelected and the other matter was approved by the required number of votes on each such matter. The final voting results were as follows:
|
Matter
|
For
|
Withheld
|
Broker
Non-votes
|
|||||||||
|
1. Election of Directors
|
||||||||||||
|
(a) Steven Kanzer
|
9,074,542
|
131,773
|
9,744,122
|
|||||||||
|
(b) Jeffrey J. Kraws
|
9,062,815
|
143,500
|
9,744,122
|
|||||||||
|
(c) James S. Kuo
|
9,058,355
|
147,960
|
9,744,122
|
|||||||||
|
(d) Jeff Riley
|
9,082,224
|
124,091
|
9,744,122
|
|||||||||
|
(e) Jeff Wolf
|
9,082,084
|
124,231
|
9,744,122
|
|||||||||
|
Matter
|
For
|
Against
|
Abstained
|
Broker
Non-votes
|
||||||||||||
|
2. Ratification of the appointment of Berman &Company LLP
|
18,228,890
|
555,529
|
166,018
|
0
|
||||||||||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: July 20, 2011
|
Adeona Pharmaceuticals, Inc.
|
|
|
(Registrant)
|
||
|
By:
|
/s/ James S. Kuo
|
|
|
Name: James S. Kuo
|
||
|
Title: Chief Executive Officer
|
||
3